We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Read MoreHide Full Article
Roche Holdings AG (RHHBY - Free Report) is set to acquire privately-held healthcare technology and services company Flatiron Health, Inc.
Both companies signed a definitive agreement whereby Roche will acquire all shares of Flatiron Health. Roche currently has an existing equity stake of 12.6%.
Roche will pay $1.9 billion for the acquisition. The transaction is expected to close in the first half of 2018.
New-York based Flatiron Health is a market leader in oncology-specific electronic health record software, as well as the curator and developer of real-world evidence for cancer research.
Per Roche, Flatiron Health is best positioned to provide the technology and data analytics infrastructure needed. Upon the closing of the deal, Flatiron Health will continue its current business model, network of partnerships and overall objectives.
Roche has been active on the acquisition front. In December 2017, Roche entered into a definitive merger agreement with Ignyta, Inc. at a price of $27 per share or total value of $1.7 billion in an all-cash transaction.
Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space with strong demand for its HER2 franchise drugs. Apart from its strong breast cancer franchise, Roche’s oncology portfolio also boasts drugs like Avastin and Tarceva for lung cancer.
Roche’s stock has lost 3.6% in the last six months as against industry's gain of 7.2%.
However, we remind investors that competition from Amgen’s (AMGN - Free Report) and Novartis’ (NVS - Free Report) biosimilars loom large on Roche’s key drugs.
Exelixis’ earnings per share estimates have moved up from 72 cents to 77 cents for 2018 in the last 60 days. The company delivered positive earnings surprise in the last four quarters, with an average beat of 572.92%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Roche Holdings AG (RHHBY - Free Report) is set to acquire privately-held healthcare technology and services company Flatiron Health, Inc.
Both companies signed a definitive agreement whereby Roche will acquire all shares of Flatiron Health. Roche currently has an existing equity stake of 12.6%.
Roche will pay $1.9 billion for the acquisition. The transaction is expected to close in the first half of 2018.
New-York based Flatiron Health is a market leader in oncology-specific electronic health record software, as well as the curator and developer of real-world evidence for cancer research.
Per Roche, Flatiron Health is best positioned to provide the technology and data analytics infrastructure needed. Upon the closing of the deal, Flatiron Health will continue its current business model, network of partnerships and overall objectives.
Roche has been active on the acquisition front. In December 2017, Roche entered into a definitive merger agreement with Ignyta, Inc. at a price of $27 per share or total value of $1.7 billion in an all-cash transaction.
Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space with strong demand for its HER2 franchise drugs. Apart from its strong breast cancer franchise, Roche’s oncology portfolio also boasts drugs like Avastin and Tarceva for lung cancer.
Roche’s stock has lost 3.6% in the last six months as against industry's gain of 7.2%.
However, we remind investors that competition from Amgen’s (AMGN - Free Report) and Novartis’ (NVS - Free Report) biosimilars loom large on Roche’s key drugs.
Zacks Rank & Stock to Consider
Roche carries a Zacks Rank #3 (Hold).
A better-ranked stock from the health care space is Exelixis (EXEL - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exelixis’ earnings per share estimates have moved up from 72 cents to 77 cents for 2018 in the last 60 days. The company delivered positive earnings surprise in the last four quarters, with an average beat of 572.92%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>